C
Cartesian Therapeutics
Biotech & Life Sciences · Gaithersburg, United States · Founded 2016 · IPO 2023
Cartesian | Developing potent, safer cell and gene therapies for cancer and autoimmune diseases - Cartesian MoreLess
Cartesian Therapeutics is a fully integrated, clinical-stage biopharmaceutical company focused on developing novel cell and gene immunotherapies. These therapies are designed to treat a range of conditions including cancer, autoimmune diseases, and respiratory diseases. Founded in 2016, the company operates in the biotechnology sector and serves patients who are in need of advanced therapeutic options. Cartesian Therapeutics combines discovery, cGMP manufacturing, and clinical operations under one roof, ensuring a streamlined process from research to patient care. The business model revolves around the development and clinical testing of its proprietary therapies, which are then licensed or sold to larger pharmaceutical companies. Revenue is generated through these partnerships, as well as through grants and research funding. The company is currently engaged in multiple active clinical trials aimed at validating the efficacy and safety of its treatments.
Keywords: cell therapy, gene therapy, cancer treatment, autoimmune diseases, respiratory diseases, biopharmaceutical, clinical trials, cGMP manufacturing, immunotherapy, biotechnology.
Talent graph
Cartesian Therapeutics's talent
Source: Dealroom Talent Intelligence.
Investors
7 investors on Cartesian Therapeutics's cap table
Sourced from Dealroom's funding and investor records.






Global footprint
Where Cartesian Therapeutics has talent and traffic
team presence
across markets
Patent intelligence
$165M patent portfolio · 43 active families
Where Cartesian Therapeutics concentrates vs peers
Each axis is a top-10 topic across Cartesian Therapeutics and its closest peers. #1 = 100, #10 = 10, absent = 0.
Source: Dealroom Patent Intelligence · Patsnap. Request a demo for the full per-sub-category breakdown, individual records, and quality-score history.
Market sentiment
What the market is saying about Cartesian Therapeutics
An AI-synthesized read of the highest-engagement posts about Cartesian Therapeutics on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Cartesian Therapeutics on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.